CryoPort (NASDAQ:CYRX) CFO Robert Stefanovich Sells 169,427 Shares of Stock

Posted by Stanley Muller on Jun 9th, 2026

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) CFO Robert Stefanovich sold 169,427 shares of CryoPort stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $16.27, for a total transaction of $2,756,577.29. Following the transaction, the chief financial officer directly owned 109,850 shares of the company’s stock, valued at approximately $1,787,259.50. This trade represents a 60.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Robert Stefanovich also recently made the following trade(s):

On Monday, March 23rd, Robert Stefanovich sold 1,094 shares of CryoPort stock. The stock was sold at an average price of $8.18, for a total value of $8,948.92.
On Monday, March 16th, Robert Stefanovich sold 2,743 shares of CryoPort stock. The stock was sold at an average price of $8.00, for a total value of $21,944.00.
On Thursday, March 12th, Robert Stefanovich sold 38,700 shares of CryoPort stock. The stock was sold at an average price of $7.76, for a total value of $300,312.00.

CryoPort Stock Performance

CYRX opened at $15.48 on Tuesday. CryoPort, Inc. has a fifty-two week low of $6.16 and a fifty-two week high of $16.73. The company has a market capitalization of $780.19 million, a P/E ratio of 11.47 and a beta of 1.90. The stock has a fifty day moving average of $11.89 and a 200-day moving average of $10.17.

CryoPort (NASDAQ:CYRX – Get Free Report) last posted its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $44.86 million. On average, equities research analysts predict that CryoPort, Inc. will post -0.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on CYRX shares. Needham & Company LLC boosted their price target on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Craig Hallum boosted their price target on CryoPort from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, June 3rd. Guggenheim upped their price target on shares of CryoPort from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. BTIG Research upped their price target on shares of CryoPort from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a report on Monday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CryoPort presently has an average rating of “Moderate Buy” and an average price target of $15.11.

Get Our Latest Stock Report on CryoPort

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Basepoint Wealth LLC acquired a new position in CryoPort during the fourth quarter worth about $34,000. Tower Research Capital LLC TRC raised its stake in CryoPort by 300.1% during the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after acquiring an additional 4,375 shares in the last quarter. AlphaQuest LLC acquired a new position in CryoPort during the third quarter worth about $79,000. Creative Planning acquired a new position in CryoPort during the second quarter worth about $96,000. Finally, Quadrature Capital Ltd acquired a new position in CryoPort during the fourth quarter worth about $97,000. Institutional investors and hedge funds own 92.90% of the company’s stock.

About CryoPort

(Get Free Report)

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.